Navigation Links
Scientists find new way to fight malaria drug resistance
Date:4/17/2014

An anti-malarial treatment that lost its status as the leading weapon against the deadly disease could be given a new lease of life, with new research indicating it simply needs to be administered differently.

The findings could revive the use of the cheap anti-malarial drug chloroquine in treating and preventing the mosquito-bourne disease, which claims the lives of more than half a million people each year around the world.

The parasite that causes malaria has developed resistance to chloroquine, but research carried out at the Australian National University (ANU) and Germany's University of Heidelberg has shown that the parasite protein that causes resistance has an Achilles' heel.

"We studied diverse versions of this protein and in all cases found that it is limited in its capacity to remove the drug from the parasite," said malaria researcher Dr Rowena Martin, from the ANU Research School of Biology.

"This means malaria could once again be treated with chloroquine if it is administered twice-daily, rather than just once a day".

Once hailed as a wonder drug, chloroquine is still used in developing nations in the South Pacific, Africa, Asia and South America, but has been withdrawn from use in many developed countries.

Dr Martin and her colleagues also revealed how the protein may have developed resistance to chloroquine.

"We found that the protein gains the ability to move chloroquine out of the parasite through one of two evolutionary pathways, but that this process is rigid one wrong turn and the protein is rendered useless," she said.

"This indicates that the protein is under conflicting pressures, which is a weakness that could be exploited in future antimalarial strategies."

Dr Martin said the findings, published in the latest Proceedings of the National Academy of Sciences of the United States of America, could be used to help millions of people in developing nations who are at risk of catching malaria.

She said that there is also potential to apply the findings to several chloroquine-like drugs that are also becoming less effective as the malaria parasite builds up resistance.

Dr Martin, however, does not recommend taking large doses of chloroquine.

"The key is to increase the frequency of chloroquine administration, for example by taking a standard dose in the morning and another at night. If you take too much all at once it can kill you," she cautions.


'/>"/>

Contact: ANU Media Office
media@anu.edu.au
026-125-7979
Australian National University
Source:Eurekalert

Related medicine news :

1. Stanford scientists develop playbook for reverse engineering tissue
2. Scientists unlock secrets of protein produced by disease-causing fungus
3. Kessler Foundation scientists receive Biogen Idec grant to study actual reality in MS
4. Scientists discover a number of novel genetic defects which cause oesophageal cancer
5. Scientists find potential target for treating mitochondrial disorders
6. Scientists describe gut bacteria that cause sepsis in preterm infants
7. Virginia Tech scientists out for blood when it comes to stopping malaria
8. U-M scientists slow development of Alzheimers trademark cell-killing plaques
9. NIH scientists track evolution of a superbug
10. In the lab, scientists coax E. coli to resist radiation damage
11. Let there be tissue-penetrating light: Scientists develop new nanoscale method to fight cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... New York, NY (PRWEB) , ... May 26, ... ... cell researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon ... Musculoskeletal Disease and Regeneration. The conference was held during May 5-6, 2016 in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... to oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) ... In this new partnership, OncLive’s editorial and marketing teams will publicize and promote ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & ... over 20 years of experience in leading technology and human resources operations for ... university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... role, Marziani will lead the company,s business development and sales team, exploring new opportunities ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
Breaking Medicine Technology: